Investigation of Neural Stem Cells in Ischemic Stroke

Ischemic Stroke Clinical Trial

— PISCES III  

Official title:

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03629275
• Other study ID #: RN01-CP-0003
• Status: Terminated
• Phase: Phase 2
• Start date: August 31, 2018
• Est. completion date: March 2, 2021

Study information

• Verified date: August 2021
• Source: ReNeuron Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study of stereotactic, intracerebral injection of CTX0E03 neural stem cells into patients with moderate to moderately severe disability as a result of an ischemic stroke.

Description:

This is a randomized, placebo-controlled, multi-center study. Patients with persistent disability 6-24 months following an ischemic stroke will be enrolled following confirmation of eligibility. Patients will be randomized 2:1 to undergo a stereotactic surgery and receive a single administration of CTX0E03 Drug Product by intracerebral implantation or undergo sham surgery only (placebo). Patients will be followed for 12 months after surgery with follow-up assessments occurring at various time points over the 12 months. All eligible patients will be assigned a standardized Physical Therapy (PT) program. Patients will complete their daily PT exercises at home for 12 weeks after their surgery.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: March 2, 2021
• Est. primary completion date: September 9, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

• Ischemic stroke that includes the supratentorial region as confirmed by CT or MRI, occurring within 6 to 24 months of the time that surgical intervention will be performed (Qualifying Stroke Event)

• Modified Rankin Score of 3 or 4 due to the Qualifying Stroke Event

• Some residual upper limb movement

• Sufficient cognitive and language abilities to comprehend verbal commands and to carry out the study assessments

• No medical conditions that would preclude neurosurgery with appropriate preparation and management.

• Ability to attend study visits and complete all study assessments including ability to provide informed consent

Exclusion Criteria:

• Modified Rankin Score of >1 prior to the Qualifying Stroke Event

• Stroke due to hemorrhage or stroke known or suspected of being caused by, or related to, connective tissue disorder, congenital disorder of the cerebral vessels or a disorder of thrombosis; patients with atrial fibrillation as a suspected cause of stroke are NOT excluded

• Neurosurgical pathway obstructed by vascular malformation or cavity

• History of neurological or other disease resulting in significant functional impairment (e.g. Parkinson's disease, motor neuron disease, moderate dementia, arthritis, contractures or fixed anatomical abnormality)

• Inability to stop or transition off valproic acid or other demethylating agents or Histone deacetylases (HDAC) inhibitors for 1 week before and 4 weeks after surgery

• Use of selective serotonin reuptake inhibitors (SSRI), unless the subject is on a stable dose that has been started at least 2-months before screening (V1)

• Use of antispasticity medications (excluding oral antispasticity medications if they have been taken regularly for at least one month prior to surgery)The use of Botox® or similar is allowed if the last dose was =3 months prior to screening; however, its use will be prohibited until following the 12 month visit

• Inability to discontinue anticoagulation therapy for a required interval

• History of malignant disease within the last 5 years, or any history of primary or secondary brain malignant disease

• Patients who have previously participated in a cell-based therapy study at any time or in any other study involving an investigational product or rehabilitation study within the last 30 days

• Patients with clinically significant lab values, including positive Class I human leukocyte antigen (HLA) antibodies specific for CTX0E03

• Planned initiation of any new PT regimen within 6-months of surgery

Related Conditions & MeSH terms

• Arm Paralysis
• Cerebral Infarction
• Chronic Stroke
• Hemiparesis
• Ischemia
• Ischemic Stroke
• Paralysis
• Paresis
• Stroke

Intervention

Combination Product:
• CTX0E03 Drug Product and delivery device
Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.

Drug:
• Placebo
Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.

Locations

Country	Name	City	State
United States	Albany Medical College	Albany	New York
United States	Emory	Atlanta	Georgia
United States	Augusta University	Augusta	Georgia
United States	Chattanooga Center for Neurologic Research	Chattanooga	Tennessee
United States	Shirley Ryan Ability Lab	Chicago	Illinois
United States	University of Miami	Coral Gables	Florida
United States	Henry Ford Health System	Detroit	Michigan
United States	Duke University School of Medicine	Durham	North Carolina
United States	JFK Neuroscience Institute	Edison	New Jersey
United States	University of Texas Health Science Center	Houston	Texas
United States	MedStar Health Research Institute	Hyattsville	Maryland
United States	University of California, Irvine	Irvine	California
United States	University of Arkansas	Little Rock	Arkansas
United States	University of California, Los Angeles	Los Angeles	California
United States	University of Southern California Neurorestoration Center	Los Angeles	California
United States	Stanford University	Palo Alto	California
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	University of Texas Health Science Center	San Antonio	Texas
United States	University of California, San Diego	San Diego	California
United States	University of South Florida	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
ReNeuron Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects in which Modified Rankin Scale (mRS) improves by =1 point at Month 6 from Baseline	The mRS is an ordinal scale from 0-6, where 0 represents no disability, and each grade above 0 represents a subject's increased level of disability and dependence upon others to perform daily activities.	6 months
Secondary	Change from baseline in a subject's ability to execute activities of daily living using the Barthel Index (BI).	The BI is an ordinal scale used to measure a patient's ability to perform activities of daily living. Sum scores from 10 items are calculated with total possible scores ranging from 0-100, with lower scores indicating increased disability.	6 months
Secondary	Change from baseline in a subject's basic mobility and balance using the Timed Up and Go Test (TUG).	TUG is a timed activity assessing mobility and balance in which subjects are asked to stand up from a chair, walk a distance of 3 meters, turn around, walk back to chair and seat themselves. Scores consist of time taken to complete the activity, in seconds.	6 months
Secondary	Change from baseline in the function of subject's paretic limb using the Chedoke Arm and Hand Activity Inventory (CAHAI).	The CAHAI is validated to assess paretic limb function and consists of 13 functional tasks, each scored on a 7-point scale, with total test scores obtained by summing each task score. Total scores can range from 13-91 with higher scores indicating greater ability.	6 months
Secondary	Change from baseline in a subject's executive processing speed, language skills and memory using the Symbol Digit Modalities Test.	Validated test assessing different aspects of cognitive function.	6 months
Secondary	Change from baseline in a subject's executive processing speed, language skills and memory using Controlled Oral Word Association tasks.	Validated test assessing different aspects of cognitive function.	6 months
Secondary	Change from baseline in a subject's executive processing speed, language skills and memory using the Multilingual Naming Test.	Validated test assessing different aspects of cognitive function.	6 months
Secondary	Change from baseline in a subject's executive processing speed, language skills and memory using the Montreal Cognitive Assessment.	Validated test assessing different aspects of cognitive function.	6 months
Secondary	Change from baseline in a subject's neurological deficits using the National Institute of Health Stroke Scale (NIHSS).	The NIHSS is comprised of 15 items used to assess severity of impairment due to stroke with each item scored on a 3 or 4 point ordinal scale in which 0 represents no impairment. Total sum score range from 0-42: higher score reflects greater severity.	6 months
Secondary	Change from baseline in restoring a subject's motor function using the Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA).	The FMA is used to assess motor function in post-stroke, hemiplegic patients. The FMA is comprised of 5 sections, and respective items within each section are scored using a 3-point ordinal scale with 0 representing inability to perform task. Total possible score is 226.	6 months
Secondary	Change from baseline in subject's global rating of change regarding their limitations of activity, symptoms, and overall quality of life.	Self-administered 2 factor questionnaire assessing change in limitations of activity, symptoms, and overall quality of life.	6 months
Secondary	Change from baseline in a subject's perception to stroke recovery using the Stroke Impact Scale (SIS).	The SIS is a stroke-specific, comprehensive measure of health status. The SIS is comprised of 59 items with each item rated on a 5 point Likert scale in terms difficulty. A score of 1 represents an inability to complete an item, where a score of 5 represents no difficulty.	6 months
Secondary	Change from baseline in a subject's health-related quality of life using the EQ-5D-5L.	Subjects rate each of 5 dimensions with a numerical rating (1-5) where 1 represents no difficulty to 5 representing an inability, and where a lower total score represents better quality of life.	6 months
Secondary	Safety: To assess the number and severity of adverse events and medical device incidents that occur over the study period.		12 months